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Abstract Nonobese diabetic (NOD) mice congenic for
C57BL/10 (B10)-derived genes in the Idd9 region of
chromosome 4 are highly protected from type 1 diabetes
(T1D). Idd9 has been divided into three protective subre-
gions (Idd9.1, 9.2, and 9.3), each of which partially prevents
disease. In this study we have fine-mapped the Idd9.1 and
Idd9.2 regions, revealing further genetic complexity with at
least two additional subregions contributing to protection
from T1D. Using the NOD sequence from bacterial artificial
chromosome clones of the Idd9.1 and Idd9.2 regions as well
as whole-genome sequence data recently made available,
sequence polymorphisms within the regions highlight a high
degree of polymorphism between the NOD and B10 strains
in the Idd9 regions. Among numerous candidate genes are
several with immunological importance. The Idd9.1 region
has been separated into Idd9.1 and Idd9.4, with Lck
remaining a candidate gene within Idd9.1. One of the Idd9.2
regions contains the candidate genes Masp2 (encoding
mannan-binding lectin serine peptidase 2) and Mtor
(encoding mammalian target of rapamycin). From mRNA
expression analyses, we have also identified several other
differentially expressed candidate genes within the Idd9.1
and Idd9.2 regions. These findings highlight that multiple,
relatively small genetic effects combine and interact to
produce significant changes in immune tolerance and dia-
betes onset.
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Introduction
T1D is a T-cell-mediated autoimmune disease resulting in
the destruction of the insulin-producing islet b cells of the
pancreas. Nonobese diabetic (NOD) mice spontaneously
develop a form of T1D controlled by more than 20 inde-
pendent gene regions, each with one or more insulin-
dependent diabetes (Idd) genes. Considerable overlap
exists between disease loci in the NOD mouse and humans
with shared susceptibility gene pathways, including genes
encoding MHC-II, insulin, IL-2/IL-2RA, CTLA-4,
NRAMP1, and PTPN22 (Wicker et al. 2005). For many of
the disease-associated regions, however, both the causative
gene(s) and mechanism(s) of susceptibility are unknown
and it is possible that common disease pathways contribute
to autoimmune susceptibility.
One such susceptibility region, Idd9, provides nearly
complete protection from diabetes development when the
Idd9NOD DNA segment is replaced with that derived from
the B10 strain (Idd9B10) (Lyons et al. 2000). Congenic mice
with progressive truncations of the Idd9 region were used to
determine that at least three independent disease genes,
Idd9.1, Idd9.2, and Idd9.3, are located within Idd9. The
immune-signaling molecule CD137/4-1BB was identified as
the candidate gene for Idd9.3 based on amino acid variation
(Lyons et al. 2000) and functional differences (Cannons
et al. 2005). We developed congenic strains isolating the
Idd9.1 (Chamberlain et al. 2006; Yamanouchi et al. 2009)
and Idd9.2 (Hamilton-Williams et al. 2009) intervals to
define the biological effects of these genes, and in the current
study we use these and additional, novel congenic strains to
fine-map the Idd9.1 and Idd9.2 regions and define candidate
genes responsible for diabetes protection.
Diabetes protective regions on chromosome 4 that over-
lap Idd9 have been characterized using congenic regions
derived from the C57BL/6 (B6) and NOR strains (Stolp et al.
2012; Tan et al. 2010). Idd11, which partially overlaps
Idd9.1, has been defined using NOD.B6 congenic strains,
and differential expression of a novel gene (AK005651, also
known as 1700003M07Rik) within the region has been
reported (Tan et al. 2010). A recent study has fine-mapped
two other protective regions overlapping Idd9.1 and Idd9.2,
but not Idd11, derived from the NOR strain, which has a
mixed genetic background derived from the NOD, B6, and
DBA/2 genomes (Stolp et al. 2012). The Idd9 region also
overlaps with a B10.NOD congenic region defining Nss1, a
gene region that influences the development of sialadenitis
(Hjelmervik et al. 2007). Although the Idd9 region does not
overlap with any known human T1D susceptibility loci, it
contains several genes of immunological significance and
genes with variations linked to other human diseases (e.g.,
genes encoding Lck, MTOR, MASP2, and CD137) (Hilde-
brandt et al. 2009; Pu et al. 2011; Sorensen et al. 2005).
A number of studies have identified immune-related phe-
notypic defects in NOD mice that are corrected by the presence
of either B10-, B6-, or NOR-derived alleles at the Idd9 over-
lapping regions. We have shown that NOD congenic mice that
carry Idd9B10 alleles have restored CD8? T-cell tolerance to
the islet antigen islet-specific glucose-6-phosphatase catalytic
subunit-related protein (IGRP) (Hamilton-Williams et al.
2010). This restored tolerance was mediated primarily by the
Idd9.2 subregion. Although CD8? T-cell tolerance was
restored by protective Idd9 alleles, intrinsic expression of these
alleles was required by CD4? T cells and a nonlymphocyte cell
type. In another study, the ability of IGRP-specific CD8? T
cells to induce diabetes was also reduced by Idd9B10 alleles
(Yamanouchi et al. 2009). Likewise, this was not due to
intrinsic expression of Idd9 genes within the CD8? T cells, but
was mediated by an Idd9.1 effect that enhanced the suppres-
sive activity of FoxP3?CD4?CD25? regulatory T cells. Idd9.3
has been found to increase the accumulation of CD137? reg-
ulatory T cells, strengthening the likelihood that the amino acid
variation in CD137 determined by Idd9.3 alleles regulates T1D
susceptibility (Kachapati et al. 2012). Islet-specific CD4?
BDC2.5 T cells expressing Idd9B10 alleles were found to be
less pathogenic than their NOD counterparts (Waldner et al.
2006). The Idd9.1B10 region reduced the islet-specific CD8?
T-cell response in a TNF-a-mediated model of T1D (Cham-
berlain et al. 2006). The NOR-derived T1D resistance loci that
overlap Idd9.1 and Idd9.2 have been shown to reduce the
pathogenic capacity of both CD4? T cells and B cells (Chen
et al. 2008; Silveira et al. 2006; Stolp et al. 2012). Lastly,
Idd9B10 alleles were found to contribute to reducing the sus-
ceptibility of b cells within islets to CTL killing, which was
linked to expression of an Idd9 candidate gene, Tnfr2 (Hill et al.
2007).
Given the large number of biological effects attributed
to genes within the Idd9/11 regions, further definition of
the polymorphic gene content within the subregions alter-
ing disease susceptibility is warranted. In the current study,
we have developed new congenic strains and refined the
genetic definition of previously characterized strains to
reduce the physical size of the Idd9.1B10 and Idd9.2B10
regions and to assess their polymorphic gene content.
Using CD8? T-cell tolerance and CD4? T-cell gene
expression as readouts, we define potential mechanisms of
disease protection mediated by polymorphic genes within
the Idd9.1B10 and Idd9.2B10 regions.
Materials and methods
Mice
Experimental procedures were performed according to the
National Institutes of Health Guide for the Care and Use of
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Fig. 1 A map of the Idd9 congenic strains used in this study. The congenic strains used to define the Idd9.1, Idd9.2, and Idd9.4 intervals and
those used in the T1D frequency studies are shown
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Laboratory Animals (IACUC #09-0074). NOD/MrkTac
and NOD-SCID (NOD/MrkBomTac-Prkdcscid) mice were
purchased from Taconic (Hudson, NY). For clarity, a dia-
gram of the congenic strains used in this study is shown in
Fig. 1. The NOD.B10 Idd9 congenic strain line 905
(NOD.B10-Idd9C57BL/10SnJ/R905MrkDvsJ) contains a con-
tinuous B10-derived DNA segment that includes T1D-pro-
tective alleles Idd9.1, Idd9.2, and Idd9.3 (Chamberlain et al.
2006; Hamilton-Williams et al. 2010; Martinez et al. 2005).
Line 905 was made by crossing line 1104 (called R28 in
Lyons et al. 2000) to NOD/MrkTac and screening for
recombinants that removed the proximal end of 1104. Lines
928 (not published previously) and 1565 (NOD.B10Sn-
Idd9.1C57BL/10SnJ/1565MrkTacJ) (Chamberlain et al. 2006;
Hamilton-Williams et al. 2010; Yamanouchi et al. 2009)
were derived by crossing line 905 to NOD/MrkTac to iden-
tify recombinants that removed the proximal Idd9.1 and
distal Idd9.2 and Idd9.3 regions, respectively. Line 2790
(Idd9.1?Idd9.3) was developed by combining the congenic
segments present in lines 1565 and 1106 (NOD.B10Sn-
Idd9.3C57BL/10SnJ/1106MrkTacJ, containing Idd9.3 and called
R35 in Lyons et al. 2000). During the development of line
2790, a new recombinant was identified that removed the
distal portion of the Idd9.1 region and line 3571 was devel-
oped. Line 1105 (having a single congenic segment encom-
passing both Idd9.2 and Idd9.3, called R11 in Lyons et al.
2000) and line 1566 (containing Idd9.2, NOD.B10Sn-
Idd9.2C57BL/10SnJ/1566MrkTacJ) have been previously
described (Cannons et al. 2005; Hamilton-Williams et al.
2010; Lyons et al. 2000; Yamanouchi et al. 2009). The
proximal end of line 1105 was defined more precisely than
previously published by screening additional markers (Sup-
plementary Table 1a). The Idd9.2-SCID strain was generated
by crossing line 1566 and NOD-SCID mice followed by
selective breeding. While making the Idd9.2-SCID line, we
identified a recombination event that isolated the proximal
portion of Idd9.2 and line 9374 was developed. After failing
to identify a recombination event that isolated the distal
portion of Idd9.2, a different approach was taken. Line 930
(unpublished, containing the distal portion of Idd9.2 in
addition to Idd9.3) was backcrossed to NOD and line 6353
was developed, isolating the distal portion of Idd9.2. The
NOD.B10 congenic line 6359 was used as the NOD control
strain in the CD8? T-cell tolerance and gene expression
studies; line 6359 contains a small B10-derived congenic
region on chromosome 1 that does not reduce diabetes inci-
dence compared with NOD (Hunter et al. 2007).
Genotyping
DNA extraction for genotyping and genotyping methods
were described previously (Fraser et al. 2010). Primer3
(Rozen and Skaletsky 2000) was used to design primers for
PCR that were then synthesized by Sigma-Genosys
(Haverhill, UK). All primers designed for this study are
listed in Supplementary Table 1b.
Variant identification
The Idd9.2 and portions of the Idd9.1/9.4 regions have been
resequenced using NOD BAC clones selected and
sequenced at the Welcome Trust Sanger Institute (Steward
et al. 2010) and deposited at the European Molecular Biol-
ogy Laboratory (http://www.ebi.ac.uk/embl/). A list of BAC
clones sequenced for each region can be found at http://
www.sanger.ac.uk/cgi-bin/Projects/M_musculus/mouse_
NOD_clones_TPF. BAC clones were selected based on
the (then current) NCBIm37 genome build. Recent
analysis of optical map data shows that the Idd9.2 tiling
path file in NCBIm37 was partly incorrect across the
proximal portion represented by congenic lines 1566 and
9374 and was restructured in the new GRCm38 mouse
genome build. The NOD genome along with the genomes
of 17 other inbred strains of mice has also been sequenced
using next-generation sequencing technology (http://www.
sanger.ac.uk/resources/mouse/genomes/). Single nucleotide
polymorphisms (SNPs) from the analyzed Idd regions were
entered into T1Dbase (Hulbert et al. 2007; Smink et al.
2005) and displayed graphically using Gbrowse (Stein et al.
2002). Variant SNPs between strains were downloaded from
the Mouse Phenome Database (http://phenome.jax.org/)
using the datasets CGD-MDA1, Broad2, WTCHG1, and
JAXSNP1. All of the annotation of the intervals can be
viewed at http://www.t1dbase.org. Ensembl annotation was
imported into T1Dbase. These Ensembl annotations are a
merged gene set derived from the manual annotation created
by the HAVANA team (Wilming et al. 2008) and the En-
sembl evidence-based automatic pipeline (Curwen et al.
2004). The Ensembl/Havana merged gene set is produced
using a method similar to that used for the human ENCODE
project (Harrow et al. 2006).
Due to the repetitive nature of the Idd9.2 region, direct
homologous gene observation between NOD and B6 was not
possible in the segmentally duplicated region. Both mouse
sequences were subjected to further manual scrutiny by the
HAVANA team using standard annotation rules and software
described on the HAVANA website (http://www.sanger.ac.
uk/research/projects/vertebrategenome/havana/). These anno-
tations were published to the Vega website (http://vega.sanger.
ac.uk/Mus_musculus/Info/Index). Nucleotide sequences of
homologous genes in the B6 and NOD Idd9.2 regions were
aligned with MAFFT v6.857, variants were derived from the
alignments using an ‘‘ad-hoc’’ Perl script, and variant
consequences were obtained with SnpEff v2.0.5d based
on annotations extracted from the HAVANA internal
database, taking the B6 as the reference genome.
E. E. Hamilton-Williams et al.: Fine mapping of Idd9.1 and Idd9.2 361
123
Virus
Recombinant vaccinia virus expressing the H-2Kd restric-
ted epitope VYLKTNVFL, amino acid residues 206–214
of murine IGRP (Vac-KdIGRP), was previously described
(Hamilton-Williams et al. 2010). Mice were infected
intraperitoneally (i.p.) with 1 9 107 PFU of virus and
CD8? T-cell responses were measured in the spleen 7 days
later by tetramer staining.
Flow cytometry
CD8? T cells were stained with H-2Kd-IGRP206-214–PE
tetramers (NIAID MHC Tetramer core facility) for 15 min
at room temperature (RT) followed by staining with anti-
CD8-FITC at 4 C for 15 min. All monoclonal antibodies
were obtained from either eBioscience (San Diego, CA),
BioLegend (San Diego, CA), or BD Pharmingen (San
Diego, CA). Cells were acquired with either a FACS
Calibur or LSRII (Becton Dickinson, Mountain View, CA)
and analyzed with FlowJo software (Tree Star, Inc., Ash-
land, OR).
Diabetes frequency studies
Female mice were tested for the presence of T1D every
7–14 days beginning at *80 days of age by the detection
of urinary glucose [500 mg/dL using Diastix (Miles,
Elkhart, IN). Diabetes frequency studies were performed at
Merck Research Laboratories, except for the experiment
depicted in Fig. 2g which was conducted at Taconic.
RNA extraction
For gene array analysis, CD4? T cells pooled from the
pancreatic lymph nodes (PcLNs) of four female 8–10-
week-old mice were stained with anti-CD4, CD44, CD62L,
and CD25 (BD Pharmingen) and sorted into naı¨ve
(CD44low CD62Lhigh CD25-), activated (CD44high
CD62Llow), central memory (CD44high CD62Lhigh), and
regulatory (CD44low CD62Lhigh CD25?) phenotype CD4?
T cells with a FACS ARIA (Becton Dickinson). For QRT-
PCR analysis, CD4? T cells were similarly sorted from
spleen cells pooled from two mice per sample. Total
nonlymphocyte spleen cells were prepared from SCID
mice by lysis of red blood cells in ACK lysis buffer (Lonza,
Walkersville, MD). Islets were isolated from the pancreas
by digestion in collagenase P and hand picking as descri-
bed (Gazda et al. 1997). RNA was extracted in TRIZOL
reagent (Invitrogen, Carlsbad, CA). RNA (500 ng) was
used to make cDNA with a High Capacity cDNA Reverse
Transcription Kit with Rnase Inhibitor (Applied Biosys-
tems, Carlsbad, CA).
DNA array sample preparation and hybridization
The Scripps Research Institute DNA Array Core Facility
performed DNA array sample preparation, hybridization,
and statistical analysis on triplicate samples. Sample
quality was checked with the Agilent 2100 Bioanalyzer
using the RNA 6000 Pico LabChip (Agilent Technologies,
Santa Clara, CA). Total RNA (5 ng) was amplified with the
WT-Ovation Pico RNA Amplification System version 1.0
(NuGEN Technologies, San Carlos, CA). Post-amplifica-
tion product was processed with the WT-Ovation Exon
Module version 1.0 (NuGEN Technologies). Post-exon
product was fragmented and labeled using the FL-Ovation
cDNA Biotin Module V2 (NuGEN Technologies). Pre- and
post-fragmentation products were checked on an RNA
6000 Nano LabChip (Agilent Technologies) using the
mRNA Assay program. The post-fragmentation and
labeling product was used for the hybridization cocktail
and hybridized overnight to the Affymetrix GeneChip
Mouse Exon 1.0 ST Array (Affymetrix, Santa Clara, CA)
following the NuGEN FL-Ovation cDNA Biotin Module
V2 protocol. Hybridization and scanning of samples to
arrays was performed using standard Affymetrix protocols
and reagents from the GeneChip Hybridization, Wash, and
Stain Kit (Affymetrix). Chips were scanned using the Af-
fymetrix GeneChip Scanner 3000 7G with default settings
and a target intensity of 250 for scaling.
DNA array statistical analysis
The DNA array analysis was run using XRAY software
version 3.9932 (Biotique Systems Inc., Reno, NV). In order
to identify genes with differential gene expression or
alternative splicing between the groups, mixed-model
analysis of variance was used. The input files were nor-
malized with full quantile normalization (Irizarry et al.
2003). Background correction was established from a pool
of probes stratified by CG content. Probe Summarization
for each probe set was derived via application of median
polish (exon RMA) to the probe scores across all input
hybridizations and probe sets. A multiple-tests correction
was performed using the Benjamini and Hochberg False
Discovery Rate method (Benjamini and Hochberg 1995).
QRT-PCR analysis
QRT-PCR analysis was performed using 12.5 ng of tem-
plate cDNA, the primers listed in Supplementary Table 1c,
with SYBR Green PCR Master Mix (Applied Biosys-
tems) on a ABI 7900 HT fast real-time PCR system
(Applied Biosystems). Expression levels were normalized
to b2 m (CD4? T-cell samples) or actin (SCID spleen and
islet samples). Actin normalization was used for the





























905 vs 928 P = 2x10-4
NOD vs 905 P = 1x10-30
NOD vs 928 P = 2x10-24
1105 vs 1106 P = 0.2
928 vs 1105 P = 5x10-4
NOD vs 1566 P = 3x10-6
NOD vs 9374 P = 0.1
9374 vs 1566 P = 8x10-4
NOD vs 1566 P = 3x10-10
NOD vs 6353 P = 6x10-3































































2790 vs 3571 P = 4x10-4
NOD vs 2790 P = 1x10-16
NOD vs 3571 P = 1x10-7
NOD vs 905 P = 1x10-21
NOD vs 1565 P = 1x10-8
NOD vs 1566 P = 1x10-10
1565 vs 905 P = 1x10-4
BA
















































































Fig. 2 Diabetes incidence of novel Idd9.1 and Idd9.2 congenic
strains. a Line 905, 1565, 1566, and NOD mice were monitored for
diabetes. b Line 2790, 3571, and NOD mice were monitored for
diabetes. c Line 1105, 1106, 1566, and NOD mice were monitored for
diabetes. Data from lines 1106, 1566, and NOD (but not 1105) in this
panel were previously published in Yamanouchi et al. (2009). d Line
905, 928, and NOD (92) were monitored for diabetes. e Combined
data from C and D. f Line 1566, 6353, and NOD mice were monitored
for diabetes. g Line 1566, 9374, and NOD mice were monitored for
diabetes
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experiment, including SCID spleen samples, as these
contain a high proportion of antigen-presenting cells,
which may upregulate b2 m upon activation.
Statistical analysis
Kaplan–Meier diabetes survival curves were plotted and
compared using the log-rank test. Differences in the fre-
quency of tetramer binding cells were compared between
groups via the Mann–Whitney test. Differences in gene
expression were compared between groups via a t test. All
tests were carried out using GraphPad Prism software
(GraphPad Software, Inc., La Jolla, CA).
Results
Refinement of the Idd9.1 genetic interval by physical
mapping
To define candidate genes responsible and interpret the
biological effects of the Idd9.1 and Idd9.2 subregions, we
developed congenic lines that isolated each protective
region independently. Idd9 was originally defined by a
44.7-cM (66.4 Mb) B10-derived interval in line 1104
(Lyons et al. 2000). The proximal portion of this interval
was truncated by 27 Mb, resulting in line 905 (Fig. 1).
Similar to the previously published diabetes frequency of
line 1104 (Lyons et al. 2000), line 905 was almost com-
pletely protected from diabetes (905 vs. NOD
P = 1 9 10-21) (Fig. 2a). This indicates that line 905 still
contains the entire Idd9 region. Backcrossing line 905 to
NOD, we screened for a recombinant that isolated Idd9.1.
Line 1565 was significantly protected from diabetes when
compared to NOD (P = 1 9 10-8), but was not as pro-
tected as line 905 (1565 vs. 905 P = 1 9 10-4) (Fig. 2a).
An independent frequency experiment performed with line
1565 showed an almost identical level of protection from
diabetes (Yamanouchi et al. 2009). This indicates that B10
alleles at the Idd9.1 region alone (line 1565) are partially
protective, but the three B10-derived Idd9 subregions
combined provide greater protection.
During the development of an Idd9.1 and Idd9.3 double
congenic strain (line 2790), we identified a recombinant
that removed the distal portion of Idd9.1 (line 3571). Both
lines 2790 and 3571 were protected from diabetes when
compared to NOD (2790 vs. NOD P = 1 9 10-16, 3571
vs. NOD P = 1 9 10-7), but line 3571 was not as pro-
tected as line 2790 (P = 4 9 10-4, Fig. 2b), indicating
that line 3571 had lost the protective effect of Idd9.1. As
line 3571 and line 1106 (Idd9.3) were not compared in the
same experiment [for reference, a previously published line
1106 incidence study is shown in Fig. 2c (Yamanouchi
et al. 2009), and an independent line 1106 incidence was
also previously published in Lyons et al. (2000)], it is not
possible to exclude the possibility that the proximal portion
of Idd9.1 found in line 3571 contains an additional weakly
protective gene. However, it is unlikely as the incidence of
line 3571 and overall incidences of line 1106 were extre-
mely similar. The difference between strains 2790 and
3571 maps the Idd9.1 protective region to 6.249 Mb.
Identification of Idd9.4
During the line 905 backcross, a recombinant was identi-
fied that removed the proximal end of the congenic region
creating line 928 (Fig. 1). Line 928 was compared to line
905 (Idd9.1, Idd9.2, and Idd9.3) in order to determine
whether the proximal portion that was removed contained a
protective gene (Fig. 2d). Line 928 was protected from
diabetes when compared to NOD (P = 2 9 10-24) but was
not as protected as line 905 (P = 2 9 10-4). This shows
that the proximal portion removed from line 928 contains a
protective gene that we continue to call Idd9.1. Combining
this incidence data with that above, our data support that
the Idd9.1 protective allele is mapped by the difference in
lines 3571 and 928, which is a 2.935-Mb region.
As line 928 contained the Idd9.2 and Idd9.3 regions, we
also compared the diabetes frequency to line 1105 (con-
taining Idd9.2 and Idd9.3). The diabetes incidence study
depicted in Fig. 2d (including line 928) was conducted at
Merck in 2000–2001. A second incidence study (including
line 1105) shown in Fig. 2c, was also conducted at Merck
in 2002–2003. As these two studies were conducted in the
same animal house relatively close in time and the fre-
quencies of diabetes in the NOD females were identical in
both studies, we compared the incidences of lines 928 and
1105 (Fig. 2e). In this analysis, line 928 was more pro-
tected than line 1105 (P = 5 9 10-4). Taken together, this
shows that line 928 contains an additional protective gene
(Idd9.4) compared to line 1105, defined by the difference
in lines 1105 and 928, a 10.626-Mb region (Fig. 1). Since
we have not developed isolated Idd9.1 and Idd9.4 strains
containing the 2.935- and 10.626-Mb intervals, respec-
tively, as defined by the results of the interval truncation
experiments described above, it is possible that the pro-
tection from T1D observed in line 1565 is due to the
combined effect of protective alleles at both the Idd9.1 and
Idd9.4 regions.
Refinement of the Idd9.2 genetic interval by physical
mapping
The Idd9.2 region was originally defined as the difference
between lines 1105 (formally R11) and 1106 (formally
R35) (Lyons et al. 2000), a 5.6-Mb region that includes the
364 E. E. Hamilton-Williams et al.: Fine mapping of Idd9.1 and Idd9.2
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candidate genes Cd30 (since renamed Tnfrsf8), Tnfr2
(since renamed Tnfrsf1b), and Mtor. In the subsequent
diabetes frequency study depicted in Fig. 2c, line 1105 was
not significantly more protected than line 1106 (P = 0.20),
although line 1105 trended to a slightly lower diabetes
frequency at 210 days. Despite this and based on the earlier
data, the Idd9.2 interval was isolated and reduced to a 3.9-
Mb region defined by strain 1566, containing more than 40
genes (Hamilton-Williams et al. 2010; Yamanouchi et al.
2009). Importantly, line 1566 does not contain Cd30 and
Tnfr2. Consistent with our previously published finding
(Yamanouchi et al. 2009) and shown here in three inde-
pendent, previously unpublished, diabetes frequency stud-
ies (Fig. 2a, f, g), line 1566 was significantly protected
from diabetes compared with NOD mice (P = 1 9 10-10,
P = 3 9 10-10, and P = 3 9 10-6), demonstrating that
this region retains Idd9.2.
To reduce the number of potential gene candidates, two
new congenic strains (lines 6353 and 9374) were produced
that contained smaller regions of Idd9.2 as defined by line
1566 (Figs. 1, 3a). Line 9374 contains the proximal half of
the Idd9.2 region, including Fbxo2 (encoding F-box protein
2), which has been implicated to have a role in diabetes
progression (Kodama et al. 2008). Line 6353 contains 10
genes, including Mtor (encoding mammalian target of
rapamycin [mTOR], diagrammed in Fig. 3b) and Masp2
(encoding mannan-binding lectin serine peptidase 2
[MASP-2], diagrammed in Fig. 3c), which both have
functions in the immune system. Unfortunately, despite
screening for recombination events within Idd9.2 in *500
mice, a recombinant mouse having the entire distal portion
of the Idd9.2 region in isolation was not identified. The
T1D frequencies of lines 9374 and 6353 were compared to
those of NOD and 1566 mice (Fig. 2f, g). Line 6353 was
significantly more protected than NOD (P = 6 9 10-3)
but less protected than line 1566 (P = 3 9 10-5). Line
9374, however, had a disease incidence that was indistin-
guishable from that of control NOD mice (P = 0.1). This
supports the hypothesis that more than one protective gene
accounts for the protection provided by line 1566, includ-
ing a gene encoded within line 6353. It remains a possi-
bility that line 9374 contains a T1D protective gene that is
only protective when a second distal Idd9.2 gene is present.
Alternatively, an additional gene may be present in the
region between lines 9374 and 6353 or distal to line 6353.
Mapping the Idd9.2 genetic interval by assessment
of CD8? T-cell tolerance to islet antigen IGRP
Previously, we showed that protection from diabetes in
Idd9 congenic mice correlates strongly with restored CD8?
T-cell tolerance to islet antigens (Hamilton-Williams et al.
2007, 2010; Martinez et al. 2005). Of the three individual
Idd9 subregions, Idd9.2 provided the strongest independent
effect on CD8? T-cell tolerance and Idd9.1 had no effect
(Hamilton-Williams et al. 2010). We therefore tested
whether either of the lines having a portion of the Idd9.2
region present in line 1566, line 9374 or 6353, had a
reduced frequency of IGRP-specific CD8? T cells. NOD,
Idd9 (905), Idd9.2 (1566), 9374, and 6353 mice were
infected with Vac-KdIGRP to expand the population of any
IGRP-specific CD8? T cells that were present (Fig. 4). As
expected, NOD mice had a high frequency of IGRP-spe-
cific CD8? T cells, which was significantly reduced in the
Idd9 (P \ 0.0001) and Idd9.2 strains (P = 0.0003). How-
ever, 6353 mice were not significantly different from NOD,
and 9374 mice were intermediate between NOD and 1566
(not significantly different from either strain). We con-
cluded that line 9374 contains a gene that has a small effect
on CD8? T-cell tolerance induction; the effect on tolerance
could reflect the activity of a gene that contributes to T1D
protection only when a second gene located in the distal
region of line 1566 is also present. However, as neither line
6353 nor line 9374 gave as strong a phenotype as the full
Idd9.2 region contained in 1566 mice, we continued to use
the Idd9.2 region defined by the 1566 strain in our sub-
sequent expression and sequence analyses.
Haplotype and sequence analysis of Idd9.1 and Idd9.4
We next performed haplotype and sequence analyses of the
Idd9.1/9.4 and Idd9.2 regions with the aim of identifying
potential SNPs that could be the causative polymorphisms
differing between the NOD and B10 strains and to help
reduce the number of potential candidate genes within the
Fig. 3 Map of the congenic strains, gene content, and SNP density of
the Idd9.2 region based on GRCm38 genome build. a The NOD.B10
congenic regions within strains 1566, 9374, 6353, and 930 are shown;
the grey bars indicate B10-derived DNA and the white bars indicate
the regions between the ‘‘in’’ and ‘‘out’’ markers. The gene content is
displayed in the T1Dbase Gene Span tract (based on GRCm38
genome build), with known genes shown in blue and pseudogenes in
red. Zinc finger family members are underlined and those with high
homology to Rex2 are also bold and italicized. The grey box contains
the region with low sequence homology between the NOD and B6
sequence. The NOD tile path track represents the sequenced NOD
BAC clones, the light grey clones are in the region with low sequence
homology to B6, and their exact position is difficult to determine. The
NOD Vega gene annotations are shown for these clones with their
Vega database gene identifier, which has the prefix OTT-
MUSG000000. The SNP density tracks are shown for the region
containing high sequence homology for BAC sequence and NGS
data; display is SNPs per 10 kb. b Detailed SNP track covering the
Mtor gene region. c Detailed SNP track covering the Masp2 gene
region. The B6/NOD SNPs tracks represent the location of the
polymorphic NOD/B6 SNPs; black, red, blue, and green lines
represent G, T, C, and A NOD alleles, respectively. Note that where
multiple SNPs are located close together the lines in the B6/NOD
SNPs track may represent more than one SNP
c
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regions. SNP data for all available strains was down-
loaded (http://phenome.jax.org/pub-cgi/phenome/mpdcgi)
and compared to identify regions of sequence variation and
regions that are identical by descent (IBD) between the B10
and NOD strains. Of the 123 strains with SNP data available,
the B10 haplotype at Idd9.1/9.4 was fully shared only by the
strains BDP/J, P/J, SEA/GnJ, and TKDU/DnJ (Supplemen-
tary Table 1). Notably, unlike much of the genome, this is a
region that is not IBD throughout for the B10 and B6 strains.
Based on this SNP analysis, the B10 strain does not share its
full haplotype at the Idd9.1/9.4 region with any of the 18
strains for which full sequence data are available (Supple-
mentary Table 2). However, there are smaller regions of IBD
shared between B10 and the 18 strains with complete geno-
mic sequence (Supplementary Table 2) and this sequence
can be used for haplotype and sequence analyses. For
example, within the Idd9.1 region, B6 and B10 are identical
across 313 kb from 129.495 to 129.808 Mb (77 identical
SNPs, Supplementary Table 2); this region contains 17
genes, including the candidate gene Lck. A sequence com-
parison with the NOD strain is shown in Fig. 5 and Supple-
mentary Table 3. Although no polymorphisms in the
predicted amino acid sequence encoded by Lck were found,
numerous polymorphisms located in noncoding regions of
the gene were present that could potentially alter Lck
expression. Coding changes in several other genes (Supple-
mentary Table 3a) as well as variation in a noncoding gene
(Supplementary Table 3b) in this highly polymorphic region
were also present, although none of the genes is a compelling
candidate gene based on its known immune function. Idd9.1
overlaps the distal portion of the NOR Resistance Locus 1
(Fig. 1), and the B10 and NOR haplotypes are IBD in this
overlapping region (Supplementary Table 2) and could
therefore share the same T1D protective allele in this region.
For the 10.626-Mb Idd9.4 susceptibility region, NOD and
B10 have the identical haplotype for the 2.592-Mb region,
from 137.091 to 139.683 Mb (Fig. 1; Supplementary
Table 2), excluding this region from containing the causa-
tive gene for Idd9.4. Only small stretches of the remaining
8 Mb of Idd9.4 are potentially IBD between NOD and B10.
There are portions of Idd9.4 where strains with a complete
genomic sequence and the B10 strain are IBD and differ
from NOD such as where B10 has 1,270 identical SNPs
compared to NZO/HlLtJ at 134.742–139.683 Mb (Supple-
mentary Table 2). These overlapping regions could be
interrogated for sequence variants as described for the Lck
region above. However, defining potential candidate genes
in this region would best be approached by first reducing the
size of Idd9.4 with additional congenic strains separating
portions of the *8-Mb congenic segment that are highly
polymorphic between the NOD and B10 strains. It is of note
that throughout much of the B10-defined Idd9.4 region that
overlaps the NOR-defined Idd25 region, which comprises
the proximal portion of the NOR Resistance Locus 2 (Fig. 1;
Supplementary Table 2), the two strains are generally not
IBD except where they are both also IBD with the NOD
strain. An exception is 136.439–137.073 Mb, where NOR
and B10 are IBD and both differ from NOD, highlighting a
region that could contain a T1D susceptibility gene shared
by Idd9.4 and Idd25. Since the B6 strain is IBD with NOR
and B10 in the 136.439–137.073-Mb region, a complete
sequence comparison can be made (data not shown).
Haplotype and sequence analysis of Idd9.2
As all 775 B6 and B10 SNPs were found to be IBD
throughout the Idd9.2 region (data not shown), we com-
pared NOD and B6 sequences across this region (Fig. 3a).
The proximal portion of the Idd9.2 region contained a high
degree of repetitive sequences and contains several
sequence breaks in the B6 assembly. As a result we were
unable to generate a continuous NOD sequence through the
proximal portion of Idd9.2 and were unable to compare the
NOD and B6 sequences for the proximal region indicated
on Fig. 3a. Homologous genes between NOD and B6 that
could not be confidently identified were annotated cau-
tiously. In particular, the sequence distal of Gm13051
becomes increasingly divergent between B6 and NOD and
breaks down almost completely distal of Zfp600. A very
high SNP density (up to 400 SNPs per 10 kb) was found
throughout the entire distal Idd9.2 region, indicative of an
ancient haplotypic divergence (Yang et al. 2011); thus, all
Fig. 4 IGRP-specific CD8? T-cell responses in Idd9.2 congenic
substrains. NOD, 9374, 6353, 1566 (Idd9.2), and 905 (Idd9) mice
were infected with Vac-IGRP and the frequency of IGRP-specific
CD8? T cells in the spleen was determined. Pooled data from six
similar experiments are shown. Horizontal line depicts median value
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genes in the region are potentially functionally polymor-
phic between B6 and NOD. Therefore, it is not possible to
narrow the number of candidate causative genes in the
Idd9.2 region by sequence analysis alone. A list of NOD/
B6 polymorphisms predicted to change the coding
sequence of known genes is found in Supplementary
Table 3c. Polymorphisms were also found in a number of
noncoding antisense RNA and long intergenic noncoding
RNA sequences (listed in Supplementary Table 3d).
The second aim of the sequence analysis was to deter-
mine the exact boundaries and gene content of the new
strains 9374 and 6353. The markers that define the proxi-
mal and distal boundaries of line 9374 are listed in Sup-
plementary Table 1a. Line 6353 has a maximum congenic
interval of 0.432 Mb and the proximal ‘‘in’’ marker of the
line 6353 recombination event is within the 7–8-intron of
the 58-exon Mtor gene, and the ‘‘out’’ marker is upstream
of Mtor. Therefore, the highly polymorphic Mtor (Fig. 3b)
remains a candidate for the protective effects of line 6353
along with the genes Angptl7, Exosc10, Srm, Masp2,
Tardbp, Gm572, Gm3487, Gm3492, and Casz1 and the
pseudogene Gm13204. Both the mTOR and MASP-2
proteins have functions associated with the immune system
and are therefore the strongest candidates within line 6353
(Sorensen et al. 2005; Thomson et al. 2009). However, we
note that the entire congenic region in line 6353 has
extensive noncoding variation (Fig. 3a) that could cause
allele-specific mRNA and protein expression differences,
and there are amino acid-changing SNPs present in Exo-
sc10, Masp2, and Casz1 and variation resulting in a frame-
shift in Gm572 (Supplementary Table 3c). As NOR and
B10 are IBD throughout the Idd9.2 region (data not
shown), it is probable that the T1D protection conferred by
the distal portion of the NOR Resistance Locus 2 is
attributable to the same non-NOD alleles (Stolp et al.
2012).
Identification of differentially expressed genes
in the Idd9 congenic regions
We have observed that intrinsic expression of Idd9 genes
within CD8? T cells was not required for protection from
the loss of CD8? T-cell tolerance, but rather expression
within CD4? T cells was required (Hamilton-Williams
et al. 2010). Considerable evidence from others also



























Fig. 5 Sequence analysis of the Idd9.1 region between 129.491 and
129.818 Mb, where B10 and B6 are IBD, and compared to NOD.
a The gene content is displayed in the T1Dbase Gene Span tract
(based on GRCm38 genome build) and the SNP density is displayed
as SNPs per 10 kb. b Detailed SNP track covering the Lck gene
region. The B6/NOD SNPs tracks represent the location of the
polymorphic NOD/B6 SNPs; black, red, blue, and green lines
represent G, T, C, and A NOD alleles, respectively. Note that where
multiple SNPs are located close together, the lines in the B6/NOD
SNPs track may represent more than one SNP
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mediated by Idd9 (Chen et al. 2008; Waldner et al. 2006;
Yamanouchi et al. 2009). Therefore, we performed a global
gene expression analysis of Idd9 versus NOD CD4? T cells
to identify potential candidate genes within Idd9.1/9.4,
Idd9.2, and Idd9.3. CD4? T cells with an activated phe-
notype (CD44high, CD62Llow) were sorted from the PcLNs
of NOD (line 6359) and Idd9 (line 905) mice. Activated
cells from the PcLN were used to obtain cells enriched for
those activated by islet antigens. Exon arrays were used to
allow detection of alternatively spliced gene isoforms (data
deposited in GEO, accession No. GSE35482). This analysis
resulted in the identification of 80 differentially expressed
known genes (fold change [1.4, adjusted P value \0.05).
However, most changes (77/80) were small and only three
genes (Akr1e1, Rex2, and Jun) had a fold change [2.0.
Analysis was also performed on the Affymetrix extended
probe set (including provisional genes and long coding
mRNAs) resulting in an additional 51 differentially
expressed probes. A list of all differentially expressed
genes and probes is found in Supplementary Table 4.
In this analysis, the two most differentially expressed
known genes were Akr1e1 (encoding aldo-keto reductase
family 1, member E1), which was highly upregulated, and
Rex2 (encoding reduced expression 2), which was highly
downregulated in Idd9 CD4? T cells. Rex2 is a zinc finger
family member contained within the line 9374 congenic
interval. The B6 proximal portion of Idd9.2 contains no
fewer than 21 zinc finger family loci (including Rex2,
underlined genes in Fig. 3a), several of which appear to be
pseudogenes. Akr1e1 is located on chromosome 13. In
order to test whether the Idd9.2 haplotype modulated
expression of these two genes, CD4? T-cell subsets were
isolated from the spleens of NOD, Idd9.1, Idd9.2, Idd9.3,
and Idd9 mice. Splenic cells were used rather than PcLN in
the QRT-PCR analysis as this provided enough material to
analyze gene expression without prior amplification of the
RNA. Akr1e1 and Rex2 expression levels were analyzed by
QRT-PCR (Fig. 6a). Akr1e1 expression in naı¨ve (CD44low
CD62Lhigh CD25-), activated (CD44high CD62Llow),
central memory (CD44high CD62Lhigh), and regulatory
(CD44low CD62Lhigh CD25?) phenotype CD4? T cells was
significantly higher in Idd9.2 and Idd9 mice than in NOD,
Idd9.1, or Idd9.3 mice. Two splice forms of Rex2 are
currently annotated: Rex2-201 and Rex2-202. Expression
of Rex2-202 was significantly lower in all CD4? T-cell
subsets tested in Idd9.2 and Idd9 mice compared with
NOD, Idd9.1, and Idd9.3 mice (P \ 0.0001, Fig. 6a). A
second primer set predicted to amplify Rex2-201 was most
significantly changed in memory phenotype CD4? T cells
(P \ 0.0001, Fig. 6a) and changed to a lesser degree in the
other subsets. This confirmed that expression of both
Akr1e1 and Rex2 was strictly dependent on Idd9.2 geno-
type. Differential expression of Akr1e1 has also been
observed, comparing B-cell mRNA obtained from NOD
mice and NOD mice congenic for the NOR-derived region
on chromosome 4 that includes NOR Resistance Locus 2
that is IBD with B10-derived Idd9.2 (Stolp et al. 2012).
As Idd9 expression was determined to be required on
nonlymphocyte cells as well as CD4? T cells (Hamilton-
Williams et al. 2009), we also compared Akr1e1 expression
in RNA isolated from Idd9.2-SCID- and NOD-SCID-
derived spleen cells and from islets. Akr1e1 expression was
significantly higher in Idd9.2-SCID splenocytes than in
NOD-SCID splenocytes (P = 0.0002, Fig. 6b). Islets were
isolated from the same NOD-SCID and Idd9.2-SCID mice,
and Akr1e1 expression was found to be significantly higher
in Idd9.2-SCID islets than in NOD-SCID islets
(P = 0.0368). We also tested whether Akr1e1 expression
was regulated by a gene within the 9374 congenic strain.
Akr1e1 expression was significantly higher in CD4? T cells
purified from line 9374 spleens than in cells from NOD
spleens (P = 0.0006, Fig. 6c), indicating that this region is
responsible for the Akr1e1 expression difference.
The microarray gene expression analysis also resulted in
the identification of a number of genes located within the
Idd9.1 region (Ccdc28b, Ptp4a2, S100pbp, Rbbp4, and
Zbtb8a), which were studied further. QRT-PCR analysis of
these genes was performed on the same CD4? T-cell
spleen samples as were Rex2 and Akr1e1. Ptp4a2, Rbbp4,
and S100pbp had putative differential expression of indi-
vidual exons (splice variants); therefore, primers were
designed to amplify the affected regions. Significant dif-
ferences in the expression of Ccdc28b, Zbtb8a, Ptp4a2, and
S100pbp were found in at least one of the CD4? T-cells
subsets examined (Fig. 7). Expression of Rbbp4 was not
found by QRT-PCR analysis to be significantly different
between the strains (data not shown). Ccdc28b, Ptp4a2,
and Zbtb8a are all located within the 2.935-Mb Idd9.1
region shown in Fig. 1. Only Ccdc28b is located within the
region of Idd9.1 that overlaps with the NOR Resistance
Locus 2 (Fig. 1; Supplementary Table 2), and this gene
was also reported to be differentially expressed in B cells
(Stolp et al. 2012).
Discussion
In this study we have developed several new congenic
strains with the aim of defining and reducing the size of the
Idd9.1 and Idd9.2 intervals. Analysis of the new strains has
revealed that there is more than one gene affecting diabetes
frequency within both regions. We have differentiated
Idd9.1 to a 2.935-Mb region and designated Idd9.4 to a
10.626-region. The 3.9-Mb Idd9.2 region was shown to
have at least two genes influencing disease susceptibility,
with one gene localized to a 0.432-Mb interval. Sequence
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Fig. 6 Gene expression differences dependent on Idd9.2. a Naı¨ve,
activated, central memory, and regulatory CD4? T cells were sorted
from splenocytes of NOD, Idd9.1 (strain 1565), Idd9.2 (strain 1566),
Idd9.3 (strain 1106), and Idd9 (strain 905) mice (each point represents
cells isolated from splenocytes pooled from two mice). QRT-PCR
was performed and gene expression relative to b2 m is plotted. For
increased statistical power, combined strains with the NOD allele at
Idd9.2 (NOD, Idd9.1 and Idd9.3) were compared with combined
strains with the B10 alleles at Idd9.2 (Idd9.2 and Idd9). b Akr1e1
expression (exons 8 and 9) relative to actin was measured in total
spleen cells and purified islets from NOD-SCID and Idd9.2-SCID
mice. c Total CD4? T cells were isolated from the spleens of NOD,
Idd9, and 9374 mice and Akr1e1 expression (exons 8 and 9) relative
to actin was measured. Line represents mean value
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analysis of the Idd9.1/4 and Idd9.2 regions revealed a high
degree of variation between the B10 and NOD strains,
which is consistent with these regions providing T1D
susceptibility. The only observed relatively large region of
IBD between the B10 and NOD strains was a 2.592-Mb
region in Idd9.4, thereby making nearly all of the genes in
the regions studied potential causal genes based on sequence
variation.
The B10-derived Idd9.1/9.4/9.2 regions overlap (Fig. 1)
with the 6.9-kb B6-derived Idd11 region (Tan et al. 2010)
and with two NOR-derived regions that protect from T1D
(Stolp et al. 2012). Although the NOD, B6, B10, and NOR
strains have unique haplotypes overall at the distal end of
chromosome 4 (McClive et al. 1994 and Supplementary
Table 2), the use of a dense SNP map allows for the def-
inition of regions where two or more strains are IBD. For
example, the B6, B10, and NOR strains are all IBD and
differ from NOD at the 6.9-kb Idd11 region that is contained
within Idd9.1, but this region has been excluded from con-
tributing to the T1D protection provided by NOR Resistance
Locus 1 (Stolp et al. 2012; Tan et al. 2010), and B10 and
NOR are not IBD with B6 in much of the remainder of the
Idd9.1 region (Supplementary Table 2). Given this, although
it is possible that the T1D-susceptibility Idd9.1 and Idd11
genes are identical, an alternative explanation is that one or
more of the many gene variants causing amino acid changes
or differential gene expression of coding or noncoding genes
between the NOD and B10 strains that differ from NOD/B6
variation in this region is responsible for the T1D protection
observed from the B10 Idd9.1 haplotype. The Idd9.4 region
overlaps with a newly identified NOR-derived protective
region called Idd25 as well as NOR Resistance Locus 2
(Stolp et al. 2012). B10 and NOR are IBD for part of this
region (136.439–138.545 Mb), although this partly overlaps
with the region where NOD and B10 are IBD, leaving the
polymorphic 136.439–137.073-Mb region that contains the
complement genes C1qa, C1ab, and C1qc, where a common
causative gene could be located. Alternatively, the B10
strain may contain a unique protective allele in the region of
Idd9.4 that is not IBD with NOR. Finally, B10 and NOR are
Fig. 7 Gene expression differences in Idd9.1 candidate genes in
CD4? T cells. Naı¨ve, activated, central memory, and regulatory
CD4? T cells were sorted from splenocytes of NOD, Idd9.1 (strain
1565), Idd9.2 (strain 1566), Idd9.3 (strain 1106), and Idd9 (strain 905)
mice (each point represents cells isolated from splenocytes pooled
from two mice). QRT-PCR was performed and gene expression
relative to b2 m is plotted. For increased statistical power, combined
strains with the NOD allele at Idd9.1 (NOD, Idd9.2, and Idd9.3) were
compared with combined strains with the B10 alleles at Idd9.1
(Idd9.1 and Idd9)
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IBD in the overlapping region encompassing Idd9.2 and the
distal portion of NOR Resistance Locus 1.
Lck has previously been proposed as a candidate gene
for the Idd9.1 region given its central role in cell signaling.
We found that Lck remains within the 2.935-Mb Idd9.1
region and is a strong candidate for contributing to the
protective effect of Idd9.1. Other candidates identified
include Ccdc28b (coiled coil domain containing 28B,
known as MGC1203 in humans) and Zbtb8a (zinc finger
and BTB domain containing 8a). A difference in Zbtb8a
and Ccdc28b expression between the NOD and B10 alleles
was previously reported in the salivary glands in a model of
sialadenitis (Hjelmervik et al. 2007). A difference in
Ccd28b expression was also reported between the NOD
and NOR (IBD with B10 at Ccd28b) alleles in B cells
(Stolp et al. 2012). Differentially expressed Ptp4a2 (pro-
tein tyrosine phosphatase 4a2, also known as protein-
tyrosine phosphatase of regenerating liver 2 or PRL-2) is a
widely expressed gene (Dumaual et al. 2006) and is found
overexpressed in some cancers (Hardy et al. 2010). We
note that it is likely the gene expression differences
between the highly polymorphic NOD and B10 Idd9.1/9.4
and Idd9.2 regions are greatly underestimated in our study
due to insufficient sensitivity of the microarray platform
and/or to the limited number of tissues and activation
conditions tested. For example, Mtor and Ephb2 expression
in B cells having the NOR allele at these genes (in a region
where NOR and B10 are IBD) differs from the expression
in B cells having the NOD allele (Stolp et al. 2012).
Changes in the noncoding, potentially regulatory, regions
of many of the highly polymorphic genes in this region
(including Mtor) could alter gene expression more promi-
nently in one cell type or another. Changes in the multiple
genes associated with T1D protection in this region of
chromosome 4 are likely related to the changes in T- and
B-cell phenotypes linked by us and others to these regions,
but attributing T1D causality to any particular cellular
phenotype within a subregion can only be speculative.
Some of the T1D causal gene variants that are broadly
expressed could influence both T- and B-cell physiology,
and the overall finding from the fine-mapping conducted in
the current study as well as that by Stolp and colleagues is
that multiple genes within the region function together to
provide the strongest alteration of multiple cellular phe-
notypes and T1D protection.
Variation in the rate of recombination across different
genomic regions is a limitation of localizing disease genes
by the congenic strain mapping approach. For example, a
recombinant mouse having the entire distal Idd9.2 con-
genic region was not identified in the current study.
Without results from such a congenic strain, we cannot
exclude that the Idd9.2 region represented in line 9374
contains a gene that alters only diabetes susceptibility when
it is expressed in combination with another gene located in
the distal portion of Idd9.2. Interestingly, line 9374 did
improve CD8? T-cell tolerance to the islet antigen IGRP,
supporting this possibility. Although the line 9374 diabetes
study had a smaller group size (n = 44) compared to that
of the line 6353 study (n = 80), and therefore had less
power to detect a small individual effect on the frequency
of diabetes as compared to the NOD strain, it was clear that
line 9374 lacked the T1D protection mediated by the full
Idd9.2 congenic interval (line 1566).
Another limitation of the congenic mapping approach is
the possibility that that multiple genes within the congenic
interval modulate diabetes incidence with opposing affect.
For example, a B10-derived diabetes susceptibility allele
Idd5.4 was discovered distal to the Idd5.2 region that
increased diabetes incidence (Hunter et al. 2007). The
presence of such a gene could mask the presence of another
protective gene in the same interval.
Sequencing of the Idd9.2 region was complicated by
the fact that the proximal portion of Idd9.2, as defined by
line 1566, is highly duplicated, which has resulted in
difficulties in providing a contiguous reference genome
sequence. The success in selecting NOD BAC ends for
sequencing across the proximal portion was dependent
upon there being significantly high homology between the
B6 and NOD mice to confidently position NOD BAC end
sequences to the reference genome (Steward et al. 2010).
The relatively poor sequence coverage of the proximal
portion of Idd9.2 in B6 and NOD can be explained by the
repetitive nature of this region and the likely occurrence
of interstrain structural variation that this causes. The
existence of such divergent regions of the mouse genome
within inbred strains of laboratory mice reflects the seg-
regation of haplotypes from at least three subspecies of
Mus musculus that diverged hundreds of thousands of
years ago (Wade et al. 2002).
The entire distal portion of Idd9.2, including the 0.432-
Mb region represented by line 6353, contains a high den-
sity of divergent SNPs when NOD and B6 sequences are
compared. Two genes with known immune system func-
tion are contained in the line 6353 B10-derived congenic
region, Mtor and Masp2. mTOR is a central signaling
kinase that receives input from insulin, growth factors, and
mitogens as well as sensing nutrient levels and redox status
and then regulates cell growth and proliferation (Zoncu
et al. 2011). The mTOR inhibitor rapamycin is an immu-
nosuppressant, inhibiting effector T-cell proliferation as
well as having diverse effects on antigen-presenting cells
and regulatory T cells (reviewed in Thomson et al. 2009).
Several variant SNPs were found within the introns of the
Mtor gene, which could hypothetically alter expression
(Fig. 3b). Idd9-dependent variation in mTOR protein
expression was not detected by flow cytometry in naı¨ve or
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activated CD8? T cells (data not shown); however, this
does not preclude that expression differences may occur in
CD8? T cells following other types of activation or in other
cell types such as B cells (Stolp et al. 2012). MASP2 is a
circulating blood protein related to the classical comple-
ment pathway protein C1. MASP2 is activated by the
binding of pathogen-derived carbohydrates, which then
allows cleavage of complement proteins C4 and C2, pro-
ducing active C3 (reviewed in Sorensen et al. 2005). A
known mutation in human MASP2 was associated with
susceptibility to severe infections and autoimmunity
(Stengaard-Pedersen et al. 2003). We detected four
nonsynonymous SNPs that varied in the Masp2 coding
region (Supplementary Table 3c; Fig. 3c). Three of the
four amino acid changes were nonconservative, supporting
Masp2 as a candidate gene contributing to Idd9.2. There
are also a large number of noncoding changes in Masp2
that could alter its expression (Fig. 3c). Although expres-
sion differences were not detected for most genes in the
Idd9.2 region, including Mtor and Masp2, the expression
variation could be underestimated as discussed above.
The proximal portion of Idd9.2 represented by line 9374
contained the gene Rex2, which had significant differential
expression between the NOD- and B10-derived alleles,
particularly in the splice variant Rex2-202. This may be
due to a SNP or SNPs in the Rex2 gene altering splicing
sites or affecting the binding of intronic or exonic splicing
enhancers or silencers. Rex2 was identified as a cDNA
expressed in teratocarcinoma cells with reduced expression
following treatment with retinoic acid (Faria et al. 1998). It
contains homology to zinc-finger-containing proteins and is
therefore a putative DNA binding protein (Faria et al.
1998). We also identified the gene Akr1e1, expression of
which was regulated by a gene found within the line 9374
congenic region. Akr1e1 is an enzyme involved in glyco-
gen metabolism. Therefore, it is possible that Rex2 mod-
ulates the transcription of Akr1e1.
Sequence analysis of the Idd9.2 distal region and the Idd9.1/
9.4 regions identified a number of SNPs and larger sequence
variations in noncoding RNAs. Some noncoding RNAs are
believed to regulate gene expression, possibly by association
with chromatin-modifying complexes (Ng et al. 2012).
Therefore, it is possible that the observed variations in non-
coding RNAs could alter their function and T1D susceptibility.
Our analysis shows the value of in-depth haplotype
analysis. While the B10 strain has not been fully
sequenced, by locating regions of IBD between B10 and
another mouse strain for which full NGS data are available,
we were able to identify variant SNPs in the region. Fur-
thermore, regions of IBD between NOD and B10 can be
identified and excluded and regions of commonality
between the NOR, B6, and B10 protective regions could be
assessed.
These studies demonstrate the difficulty of mapping
disease susceptibility loci in complex genetic diseases,
especially when it is possible that both protective and
susceptible alleles are in linkage disequilibrium (Hunter
et al. 2007). We and others have found that highly pro-
tective loci identified in segregation analyses and then
confirmed with congenic strains having large regions from
the parental strain are almost always ultimately shown to
result from multiple disease genes (Fraser et al. 2010;
Lyons et al. 2000; Serreze et al. 1998; Wicker et al. 2004).
Many of these genes with small individual effects on dis-
ease can be localized by refining congenic intervals as
shown in the current study. However, even when defined to
less than 0.5 Mb, as done for line 6353, a congenic region
still contains multiple polymorphic genes associated toge-
ther as an ancient haplotypic block (Yang et al. 2011).
Although genes with known immunological functions
usually become the likely candidate genes, most of the
genes encode proteins not previously associated with
autoimmunity. It also remains possible that even in a
region as small as that in 6353, there is more than one
causal gene.
Nevertheless, genetic mapping studies such as this have
resulted in the identification of clear single-gene candidates
(Fraser et al. 2010; Jordan et al. 2011). Haplotype mapping
analysis has been used to identify a key SNP in the Ctla4
gene, which was then further verified as a causative poly-
morphism responsible for Idd5.1 (Araki et al. 2009).
Similarly, haplotype mapping was of key importance in the
verification of the interleukin-2 gene as the basis of Idd3
(Yamanouchi et al. 2007). Therefore, despite the difficulty
in resolving the complex Idd9.1/4 and Idd9.2 loci, such
genetic mapping studies remain of importance in defining
disease susceptibility loci in both mouse and man.
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